New Study Shows How Staph Toxin Disarms the Immune System, Reveals Secret to Microbe’s Deadly Versatility
Findings Point the Way to New Class of Antibiotics
Researchers at NYU Langone Medical Center have discovered a new mechanism by which the deadly Staphylococcus aureus bacteria attack and kill off immune cells. Their findings, published today in the journal Cell Host & Microbe, explain a critical survival tactic of a pathogen that causes more skin and heart infections than any other microbe, and kills more than 100,000 Americans every year.
“What we’ve found is that Staph unleashes a multi-purpose toxin capable of killing different types of immune cells by selectively binding to surface receptors,” says Victor J. Torres, PhD, assistant professor of microbiology, and senior author of the study. “Staph has evolved the clever ability to target the immune system at different stages.”
Scientists have long known that Staph releases an arsenal of toxins to puncture immune cells and clear the way for infection. But only recently have they begun to understand exactly how these toxins work. Earlier this year, Dr. Torres and his team published a paper in Nature explaining how one of those toxins, a protein called LukED, fatally lyses T-cells, macrophages and dendritic cells, all types of white blood cells that help fight off infection. The LukED toxin, they showed, binds to a surface receptor called CCR5 (the same one exploited by HIV). “It attaches to the surface receptor and then triggers pore formation,” says Dr. Torres. But their discovery failed to explain how the bacterial toxin kills other types of white blood cells, such as neutrophils, that lack the CCR5 receptor.
Their most recent work solves this puzzle, showing for the first time how receptors on neutrophils (a common type of white blood cell) also enable binding of the LukED toxin. The researchers found that LukED latches onto surface receptors called CXCR1 and CXCR2, creating the same deadly pores that it does when it latches onto CCR5 receptors. “The mechanism is the same,” says Dr. Torres. “The strategy makes Staph deadlier in mice.”
Neutrophils are the first responders. Upon infection, they race through the bloodstream to kill off the invading pathogen. “They’re like the marines of the immune system,” Dr. Torres says. T-cells, macrophages and dendritic cells rush in later, mounting a secondary attack to help the body clear the pathogen and remember it in the future. “Killing off the first responders completely disarms the immune system,” Dr. Torres says.
LukED is just one piece of the puzzle, and more research is needed to understand other Staph toxins and how they work together to make the microbe deadlier. However, these recent insights hold promise for new medications that target LukED. Better treatments against Staph are desperately needed. In 2005, the Centers for Disease Control and Prevention estimated that more than half of the 478,000 people hospitalized for staph infections were resistant to methicillin, one of the most potent antibiotics available.
One therapeutic strategy is to block CCR5 receptors and spare the secondary immune response. “We know we can block CCR5 receptors without crippling the rest of the immune system. Some people lack CCR5 and they are perfectly healthy and immune to HIV as well,” Dr. Torres says. “But just blocking CCR5 isn’t enough.” Drugs are available to block CXCR1 and CXCR2 receptors, but those will impair neutrophil recruitment and function. “The lesson is to target the toxin itself and prevent it from attaching to any receptors,” Dr. Torres adds. “We have to think globally.”
Other NYU School of Medicine researchers contributing to the study are Tamara Reyes-Robles, Francis Alonzo III, PhD, Lina Kozhaya and Derya Unutmaz, MD.
The study was funded by grants from the National Institutes of Health, the NYU School of Medicine Development Funds, and an American Heart Association Scientist Development Grant.